Anti-Atezolizumab (TECENTRIQ) ELISA Assay Kit
The Anti-Atezolizumab (TECENTRIQ) ELISA Assay Kit is For Research Use Only
Size: 12×8 wells
Sensitivity: +/-
Incubation Time: 2 hours 20 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µl
Alternative Name: Tecentriq
Assay Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L l and PD-1, removing inhibition of immune responses seen in some cancers. Atezolizumab is a humanized IgG antibody that binds PD-Ll, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-Ll and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. Atezolizumab is indicated to treat locally or advanced metastatic urothelial carcinoma in patients ineligible forcicplatin-containing chemotherapy with tumors expressing PD- L l, in patients ineligible for cisplatin-containing chemotherapy irrespective of PD-Ll, have disease progression following platinum containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapy. Atezolizumab is also indicated first line for non small cell lung cancer in combination with bevacizumab, paclitaxel, and carboplatin with no EGFR or ALK genomic abnormalities. It can be used in patients with disease progression during or after platinum containing chemotherapy even if they have EGFR and ALK abnormalities. Atezolizumab is indicated in combination with paclitaxel protein-bound to treat locally advanced or metastatic triple negative breast cancer expressing PD-L l.
Assay Principle
Solid phase enzyme-linked immunosorbent assay {ELISA) based on the sandwich principle. Controls and samples {serum or plasma) are incubated in the microtiter plate coated with the drug Atezolizumab. After incubation, the wells are washed. Then, horse radish peroxidase {HRP) conjugated probe is added and binds to Atezolizumab antibodies captured by the drug Atezolizumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of Atezolizumab antibodies in the sample or controls. The results can be evaluated with using cut- off value.
Related Products
Atezolizumab ELISA Assay Kit
Anti-Daratumumab (Darzalex) ELISA Assay Kit
Anti-Rituximab ELISA Assay Kit
